HCC
Conditions
Interventions
B:TACE+PD-1
Sponsors
Chinese PLA General Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Age: >= 18 years old, <= 75 years old; 2. Clinical or pathological diagnosis of HCC; 3. Complete clinical, laboratory and imaging data; 4. The liver tumor burden is less than 70% (the tumor accounts for the volume of the entire liver), and there is no main portal vein tumor thrombus, or although there is a trunk tumor thrombus, but the collaterals are well established; 5. CNLC stage IIb-IIIb stage of liver cancer; 6. Child-Pugh classification A or B; 7. ECOG-PS score: 0-2 points; 8. There are no other contraindications for angiography (such as contrast agent allergy, uncontrolled infection, uncorrectable coagulation disorder, etc.); 9. There are no contraindications to the use of PD-1 (eg: autoimmune diseases, history of organ transplantation, etc.); 10. The subjects voluntarily joined the study, signed the informed consent, and were able to cooperate with the follow-up and complete the research project.
Exclusion criteria
Exclusion criteria: 1. ECOG-PS score >= 2; 2. Child- Pugh grade C; 3. Abnormal coagulation function (INR>1.5 or prothrombin time (PT)> ULN 4 seconds), with bleeding tendency or receiving thrombolytic or anticoagulant therapy; 4. the presence of grade II or more myelosuppression; 5. active period of infectious diseases; 6. Those who have severe heart, lung, kidney, brain and other basic diseases and cannot tolerate interventional therapy; 7. Those who cannot tolerate a complete treatment cycle (>= 2 times) and cannot objectively evaluate the efficacy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Size; | — |
Countries
China
Contacts
Public ContactMao Qiang Wang
Outcome results
None listed